Polydendritic Nano-Adjuvant
Perpetuum starts pre-clinical stage investigation of it’s proprietary Polydendritic Nano-Adjuvants for novel vaccination strategies.
Perpetuum starts pre-clinical stage investigation of it’s proprietary Polydendritic Nano-Adjuvants for novel vaccination strategies.
Perpetuum launches it’s new brand Ombium, a nutritional supplement line targeting metabolic syndrome risk factors.
Perpetuum set to launch the world’s first acne treatment based on it’s recombinant bacteriophage endolysin technology
Perpetuum opens new division in China for the sales of it’s cosmetic consumer brands throughout APAC.